Louis Moore Bacon's RARE Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 200,000 shares of Ultragenyx Pharmaceutical Inc. (RARE) worth $4.6 M, representing 0.07% of the portfolio. First purchased in 2015-Q1, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in RARE, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2023, adding 75,000 shares. Largest reduction occurred in Q4 2025, reducing 70,000 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Ultragenyx Pharmaceutical (RARE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ultragenyx Pharmaceutical (RARE) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -70,000 | Reduce 25.93% | 200,000 | $23.00 |
| Q3 2025 | -20,000 | Reduce 6.90% | 270,000 | $30.08 |
| Q2 2025 | +50,000 | Add 20.83% | 290,000 | $36.36 |
| Q1 2025 | -5,000 | Reduce 2.04% | 240,000 | $36.21 |
| Q2 2024 | +60,000 | Add 32.43% | 245,000 | $41.10 |
| Q4 2023 | +35,000 | Add 23.33% | 185,000 | $47.82 |
| Q3 2023 | +45,000 | Add 42.86% | 150,000 | $35.65 |
| Q2 2023 | +75,000 | Add 250.00% | 105,000 | $46.13 |
| Q1 2023 | +30,000 | New Buy | 30,000 | $40.10 |
| Q1 2016 | -32,000 | Sold Out | 0 | $0.00 |
| Q4 2015 | +32,000 | New Buy | 32,000 | $112.19 |
| Q2 2015 | -35,000 | Sold Out | 0 | $0.00 |
| Q1 2015 | +35,000 | New Buy | 35,000 | $62.09 |
Louis Moore Bacon's Ultragenyx Pharmaceutical Investment FAQs
Louis Moore Bacon first purchased Ultragenyx Pharmaceutical Inc. (RARE) in Q1 2015, acquiring 35,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Ultragenyx Pharmaceutical Inc. (RARE) for 16 quarters since Q1 2015.
Louis Moore Bacon's largest addition to Ultragenyx Pharmaceutical Inc. (RARE) was in Q2 2023, adding 105,000 shares worth $4.84 M.
According to the latest 13F filing for Q4 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 200,000 shares of Ultragenyx Pharmaceutical Inc. (RARE), valued at approximately $4.6 M.
As of the Q4 2025 filing, Ultragenyx Pharmaceutical Inc. (RARE) represents approximately 0.07% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Ultragenyx Pharmaceutical Inc. (RARE) was 290,000 shares, as reported at the end of Q2 2025.